Ovarian hyperstimulation syndrome: an overview and prevention approaches

Articles in Press

Document Type : Original Article

Authors

1 clinical pharmacy department, faculty of pharmacy, Minia university

2 pharmaceutics department, faculty of pharmacy, Minia University

3 Pharmaceutics dept, Facult of Pharmacy, Minia Universit

4 Obstetrics and Gynecology department, Faculty of Medicine, Minia University

5 Clinical Pharmacy Department, Faculty of Pharmacy, Minia University

Abstract

Background
Ovarian hyperstimulation syndrome (OHSS) occurs as a consequence of prompt during the luteal phase of ovulation. The syndrome manifests primarily as ascites and pleural effusion, with pericardial effusion occurring rarely. Severe forms accompanied by electrolyte changes, cardiac, hepatic, renal, and hemodynamic problems linked with increased thromboembolic risk.
Main body
Inflammatory mediators, human chorionic gonadotropin, and vascular endothelial growth factor are all included in the pathophysiology of Ovarian hyperstimulation syndrome. Many risk factors affect the syndrome such as body weight, polycystic ovary syndrome, previous OHSS, estradiol level, etc. There are primary and secondary prevention methods to reduce the occurrence of the syndrome.
Conclusion
In GnRH antagonist cycles, gonadotropin-releasing hormone (GnRH) agonist trigger & GnRH agonist triggering have been identified as the most efficient measures for OHSS prevention. Coadministration of dopaminergic agonist & mild ovarian stimulation was demonstrated to be safe & efficacious.
Keywords: Ovarian hyperstimulation, Human chorionic gonadotropin, GnRH agonist, GnRH antagonist, and Estradiol.

Keywords

Upper Egypt Critical Care Journal

Articles in Press, Accepted Manuscript
Available Online from 20 July 2024

Files

Share

How to cite

Statistics